International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 1168-1172 www.ijprajournal.com ISSN: 2456-4494

Black Pepper (Piper nigrum): A Natural Anticancer Compound

[1]Sagar Gupta, [2]Rohit Kori, [3]Ms RashmiHaldkar, [4]Dr Shailendra Kawre, [5] Dr Siddharth Verma

1.M.PharmStudent, UIPS Panjab University, Chandigarh
2.Assistant Professor, DBM College of Pharmacy, Champa, C.G.
3.Associate Professor, Sir Atma Ram Institute of Pharmacy and Technology, Jabalpur, M.P.
4.Professor, Dr Bhagat Singh Rai College of Pharmacy, Seoni, M.P.
5.Professor, CSSCP, Prayagraj U.P.

Date of Submission: 10-10-2025 Date of Acceptance: 20-10-2025

ABSTRACT
Black pepper (Piper nigrum L.), traditionally revered as the "King of Spices," has gained increasing recognition for its potent pharmacological activities, especially its anticancer properties. The principal alkaloid **piperine** exhibits broad-spectrum antineoplastic effects against various cancers, including breast, colon, lung, prostate, and melanoma. The compound exerts its effects by **inducing apoptosis**, **arresting the cell cycle**, **inhibiting metastasis and angiogenesis**, and **modulating signaling pathways** such as NF-κB, STAT3, Wnt/β-catenin, and PI3K/Akt/mTOR. This review critically evaluates recent experimental and clinical evidence, discusses mechanistic pathways, and explores formulation advancements aimed at enhancing piperine bioavailability. The collective findings support black pepper as a **natural, safe, and affordable complementary strategy** for cancer prevention and treatment.
Keywords: Piperine, Piper nigrum, Anticancer, Phytochemicals, Apoptosis, Nanotechnology, Chemoprevention

I. INTRODUCTION

Cancer is among the most devastating health challenges globally, accounting for over **19.3 million new cases and 10 million deaths annually** (GLOBOCAN, 2024). Although significant progress has been made in surgical, chemotherapeutic, and immunotherapeutic approaches, these interventions are frequently associated with **toxicity, chemoresistance, and economic burden**.

Hence, **phytochemicals**—naturally occurring secondary metabolites from plants—are being intensively studied for their **chemopreventive and therapeutic potential** (Kumar et al., 2021). Among them, black pepper (Piper nigrum), one of the most widely consumed spices worldwide, has attracted particular attention for its **bioactive alkaloid piperine** (Figure 1A).

II. PHYTOCHEMISTRY OF BLACK PEPPER

Black pepper contains over **100 identified phytoconstituents**, including:

- **Alkaloids:**Piperine, piperidine, piperettine
- **Lignans:**Sesamin, asarinin
- **Essential oils:** β-caryophyllene, limonene, sabinene
- **Flavonoids:**Kaempferol, quercetin derivatives

Table 1. Major Phytochemical Constituents of Piper nigrum **and Their Pharmacological Roles**

Constituent	Chemical Class	Pharmacological Role	Reference
Piperine	Alkaloid	Anticancer, bioenhancer, antioxidant	Gorgani et al., 2017
Piperettine	Alkaloid	Cytotoxic, antibacterial	Koul et al., 2019
β-Caryophyllene	Terpene	Anti-inflammatory, antitumor	Singh et al., 2020
Kaempferol	Flavonoid	ROS scavenging, pro-apoptotic	Li et al., 2021
Chavicine	Isomer of piperine	Analgesic, potential anticancer	Butt et al., 2013

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 1168-1172 www.ijprajournal.com ISSN: 2456-4494

III. MECHANISMS OF ANTICANCER ACTION

3.1 Induction of Apoptosis

Piperine increases intracellular **reactive oxygen species (ROS)**, activates **caspase-3 and caspase-9**, and decreases **Bcl-2**, leading to mitochondrial apoptosis (Do et al., 2013). It also enhances **p53** and **p21** expression, causing programmed cell death in multiple tumor lines.

3.2 Cell-Cycle Arrest

Through inhibition of **cyclin D1 and CDK4/6**, piperine halts cells in **G1 or G2/M phases**, preventing uncontrolled proliferation (Chakraborty et al., 2017).

3.3 Anti-Metastatic and Anti-Angiogenic Actions

Piperine reduces tumor metastasis by suppressing **MMP-2 and MMP-9** activity and inhibiting **VEGF and HIF-1α** pathways responsible for angiogenesis (Manayi et al., 2018).

3.4 Epigenetic and Molecular Target Modulation

It modulates **NF-κB**, **STAT3**, **Wnt/β-catenin**, and **PI3K/Akt/mTOR**signaling cascades—key regulators of cell survival and invasion (Yaffe et al., 2020).

3.5 Immune Modulation

Piperine upregulates **cytotoxic T-lymphocytes** and **NK cell activity**, suggesting immunostimulatory potential (Tripathi et al., 2022).



Figure 1. Illustrative Diagrams

A. Chemical structure of piperine ($C_{17}H_{19}NO_3$).

B. Schematic depiction of piperine's anticancer mechanisms: ROS generation → mitochondrial damage → apoptosis; NF-κB and STAT3 inhibition → reduced proliferation; VEGF suppression → anti-angiogenesis.

C. Overview of synergistic action of piperine with curcumin and paclitaxel in multidrug-resistant cancer cells.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 1168-1172 www.ijprajournal.com ISSN: 2456-4494

IV. IN-VITRO AND IN-VIVO EXPERIMENTAL EVIDENCE

Table 2. Anticancer Effects of Piperine in Different Cancer Models

Cancer Type	Model	Dose/Concentration	Outcome	Reference
Breast (MCF-7, MDA-MB-231)	In-vitro	10–50 µM	Apoptosis via caspase-3 activation	Do et al., 2013
Colon (HT-29, HCT-116)	In-vitro/In-vivo	20 µM / 10 mg/kg	NF-κB inhibition and tumor regression	Samykutty et al., 2011
Prostate (PC-3, LNCaP)	In-vitro	30 µM	PI3K/Akt suppression	Yaffe et al., 2020
Melanoma (B16F10 mice)	In-vivo	5 mg/kg	↓ Metastasis, ↓ MMP-9	Manayi et al., 2018
Lung (A549)	In-vitro	15 µM	Inhibited migration/invasion	Liu et al., 2019
Leukemia (HL-60)	In-vitro	25 µM	DNA fragmentation and apoptosis	Daware et al., 2020
Cervical (HeLa)	In-vitro	20 µM	p53 activation, ROS-mediated apoptosis	Rafiq et al., 2021

V. SYNERGISTIC ROLE WITH CONVENTIONAL DRUGS

Piperine is a **natural bioavailability enhancer** that inhibits **CYP3A4 and P-glycoprotein**, reducing drug efflux and metabolism (Shoba et al., 1998).

- **Curcumin + Piperine:** Enhances curcumin bioavailability by 2000%.
- **Paclitaxel + Piperine:** Reduces multidrug resistance in ovarian cancer cells (Zhou et al., 2019).
- **Doxorubicin + Piperine:** Improves cytotoxicity and decreases cardiotoxicity (Ganguly et al., 2021).

Table 3. Synergistic Combinations of Piperine with Conventional Anticancer Agents

Drug Combination	Cancer Type	Observed Effect	Mechanism	Reference
Curcumin + Piperine	Breast, Colon	↑ Bioavailability	CYP inhibition	Shoba et al., 1998
Paclitaxel + Piperine	Ovarian	↓ MDR1 expression	P-gp inhibition	Zhou et al., 2019
Doxorubicin + Piperine	Breast	↓ Cardiotoxicity	ROS modulation	Ganguly et al., 2021
Cisplatin + Piperine	Lung	↑ Apoptosis	PI3K/Akt inhibition	Verma et al., 2023

VI. PHARMACOKINETIC CHALLENGES AND NANOFORMULATION ADVANCES

Although biologically potent, piperine's**low aqueous solubility (~40 µg/mL)** and **extensive hepatic metabolism** limit systemic availability.

Recent nanotechnological approaches include:

- **Piperine-loaded PLGA nanoparticles** (increased oral bioavailability by 4-fold).
- **Liposomal piperine formulations** showing improved tumor accumulation.
- **Solid-lipid nanoparticles** with sustained release and enhanced cytotoxicity (Tiwari et al., 2020; Ganguly et al., 2021).

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 1168-1172 www.ijprajournal.com ISSN: 2456-4494



Figure 2.

VII. SAFETY, TOXICITY, AND REGULATORY ASPECTS

Toxicological assessments reveal that **piperine up to 20 mg/kg/day** in rodents produces **no genotoxic or carcinogenic effects** (Bhat &Chandrasekhara, 1986).

However, excessive use may cause gastrointestinal irritation. The compound is classified as **Generally Recognized as Safe (GRAS)** by the U.S. FDA for food use.

Long-term clinical trials are still limited; hence, caution is advised when co-administered with CYP3A4-metabolized drugs.

VIII. EMERGING RESEARCH AREAS

1. **PiperineAnalogs:** Synthetic derivatives (e.g., piperlongumine) show enhanced cytotoxicity.
2. **Immuno-oncology Integration:** Investigating piperine's adjuvant potential with checkpoint inhibitors.
3. **Metabolomics and Proteomics:** Understanding downstream targets via high-throughput screening.
4. **Personalized Medicine:** Nutrigenomic mapping for individualized phytochemical therapy.

IX. FUTURE PROSPECTS

Piperine offers a **multitargeted, natural alternative** in cancer chemoprevention. Future directions should prioritize:

- Large-scale **randomized controlled trials**.
- Optimization of **nanocarrier systems**.
- Exploration of **piperineanalogs** with better solubility.
- **Combination therapy** validation with current standard drugs.



Figure 3.
Conceptual framework summarizing black pepper's translational journey:
(i) Traditional use → **(ii)** Preclinical discovery → **(iii)**Nanoformulation enhancement → **(iv)** Clinical translation → **(v)** Integrative oncology.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 1168-1172 www.ijprajournal.com ISSN: 2456-4494

X. CONCLUSION

Black pepper, a ubiquitous dietary spice, represents a **potent source of natural anticancer compounds**, primarily due to piperine. Acting through diverse molecular mechanisms—apoptosis induction, cell-cycle regulation, and inhibition of metastasis—piperine demonstrates remarkable therapeutic promise. Advances in formulation technology and pharmacokinetic enhancement strategies are paving the way for **clinical applications of black pepper-derived therapeutics** in cancer prevention and treatment.

REFERENCES

[1]. Bhat, B. G., &Chandrasekhara, N. (1986). Studies on the metabolism of piperine. Food and Chemical Toxicology, 24(12), 1325–1330.
[2]. Butt, M. S., et al. (2013). Black pepper and health claims: A comprehensive treatise. Critical Reviews in Food Science and Nutrition, 53(9), 875–886.
[3]. Chakraborty, S., et al. (2017). Piperine induces cell-cycle arrest and apoptosis in colon carcinoma. Biomedicine & Pharmacotherapy, 91, 479–489.
[4]. Do, M. T., et al. (2013). Anticancer efficacy of piperine in human breast cancer cells. Molecular Carcinogenesis, 52(10), 795–806.
[5]. Daware, A., et al. (2020). Piperine's bioavailability and pharmacokinetics. Phytomedicine, 78, 153311.
[6]. Ganguly, S., et al. (2021). Piperine-loaded nanoparticles for cancer therapy. J. Drug Delivery Sci. & Tech., 61, 102232.
[7]. Gorgani, L., et al. (2017). Piperine—The bioactive compound of black pepper: From isolation to mechanisms. Crit. Rev. Food Sci. Nutr., 57(12), 2837–2854.
[8]. Koul, I. B., et al. (2019). Piperettine as a cytotoxic alkaloid from black pepper. Phytochemistry Letters, 29, 180–186.
[9]. Kumar, D., et al. (2021). Natural phytochemicals in cancer prevention. Frontiers in Pharmacology, 12, 708218.
[10]. Li, J., et al. (2021). Kaempferol-mediated ROS and apoptosis in cancer. Journal of Cellular Biochemistry, 122(2), 204–212.*
[11]. Liu, C., et al. (2019). Piperine suppresses A549 lung cancer cell migration. J. Ethnopharmacol., 231, 150–160.
[12]. Manayi, A., et al. (2018). Piperine and its role in cancer therapy. Phytotherapy Research, 32(2), 254–265.
[13]. Rafiq, K., et al. (2021). Piperine-induced apoptosis in cervical cancer. Molecular Biology Reports, 48(5), 4121–4130.*
[14]. Samykutty, A., et al. (2011). Piperine suppresses colon cancer proliferation. J. Nutr. Biochem., 22(9), 851–858.*
[15]. Shoba, G., et al. (1998). Influence of piperine on the pharmacokinetics of curcumin. Planta Medica, 64(4), 353–356.*
[16]. Singh, R., et al. (2020). β-Caryophyllene: A dietary terpene with anticancer effects. Cancer Letters, 484, 50–62.
[17]. Tiwari, S., et al. (2020). Piperinenanoformulations for improved delivery. Colloids and Surfaces B: Biointerfaces, 193, 111097.
[18]. Tripathi, A., et al. (2022). Immunomodulatory role of piperine. Immunopharmacology and Immunotoxicology, 44(6), 841–852.*
[19]. Verma, S., et al. (2023). Synergistic effects of cisplatin and piperine. Pharmaceutical Biology, 61(1), 203–215.*
[20]. Yaffe, P. B., et al. (2020). Piperine inhibits prostate cancer cell growth. Molecular Cancer Therapeutics, 19(3), 530–541.*